Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 19 Oct 2017
At a glance
- Drugs WX UK1 (Primary) ; Capecitabine
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG.
- 25 Jan 2008 Status changed from recruiting to completed; reported by Wilex in a media release.
- 26 Aug 2005 New trial record.